Publications by authors named "Stephanie Scherrier"
Article Synopsis
- Epithelial ovarian cancer management has improved, but many patients still face diagnosis at advanced stages and experience relapses after initial treatment.
- Chemotherapy is the primary adjuvant treatment for early-stage tumors (FIGO stage I and II), while advanced-stage tumors (FIGO stage III/IV) typically receive carboplatin and paclitaxel-based chemotherapy, often combined with targeted therapies like bevacizumab and PARP inhibitors.
- Decisions regarding maintenance therapy depend on various factors, including FIGO stage, tumor characteristics, timing of surgery, residual tumor presence, chemotherapy response, and genetic factors such as BRCA mutations and HR status.
Background: Endometrioid borderline ovarian tumor (EBOT) is a rare subtype of borderline ovarian malignancies. This study was designed to determine the prognosis of a series of EBOT.
Methods: This is a retrospective review of patients with EBOT treated in or referred to our institutions and a centralized, histological review by a reference pathologist.